Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...
Zacks.com on MSN1h
Gilead Sciences (GILD) Stock Dips While Market Gains: Key FactsThe most recent trading session ended with Gilead Sciences (GILD) standing at $93.85, reflecting a -1.57% shift from the previouse trading day's closing. This move lagged the S&P 500's daily gain of 0 ...
Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th ...
The stock's fall snapped a two-day winning streak.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a ...
With the FDA approval of Gilead's seladelpar, there have now been two in a matter of weeks. The US agency has cleared seladelpar under the Livdelzi brand name as a second-line therapy for PBC in ...
and Logos Capital, as well as existing investors. Goldman Sachs’ life sciences managing director Colin Walsh has joined Attovia’s board. Goldman Sachs also led a $95 million third-round ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback